Summit Therapeutics

Summit Therapeutics appears in 156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开 as [[Akeso|康方生物]]’s overseas partner around a [[PD1VEGFBispecific|PD-1/VEGF bispecific]] asset. The episode uses Summit’s stock-market and acquisition-expectation disappointment to illustrate why 2026 interpretation cannot stop at BD excitement.

The source-scoped issue is evidence translation: strong PFS can generate enthusiasm, but OS, trial design, regulatory interpretation, and commercial development still decide whether the asset supports the market story.

Connections

• Akeso / 康方生物 - Chinese partner and source asset origin.
• PD-1/VEGF Bispecific and Progression-Free vs Overall Survival - clinical-data frame.
• Biotech BD Data Validation Phase - 2026 evidence-readout context.